Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.
Chlamydia has been shown to evade host-specific IFN-gamma-mediated bacterial killing; however, IFN-gamma-deficient mice exhibit suboptimal late phase vaginal Chlamydia muridarum clearance, greater dissemination, and oviduct pathology. These findings introduce constraints in understanding results from murine chlamydial vaccination studies in context of potential implications to humans. In this study, we used mice deficient in either IFN-gamma or the IFN-gamma receptor for intranasal vaccination with a defined secreted chlamydial Ag, chlamydial protease-like activity factor (CPAF), plus CpG and examined the role of IFN-gamma derived from adoptively transferred Ag-specific CD4+ T cells in protective immunity against genital C. muridarum infection. We found that early Ag-specific IFN-gamma induction and CD4+ T cell infiltration correlates with the onset of genital chlamydial clearance. Adoptively transferred IFN-gamma competent CPAF-specific CD4+ T cells failed to enhance the resolution of genital chlamydial infection within recipient IFN-gamma receptor-deficient mice. Conversely, IFN-gamma production from adoptively transferred CPAF-specific CD4+ T cells was sufficient in IFN-gamma-deficient mice to induce early resolution of infection and reduction of subsequent pathology. These results provide the first direct evidence that enhanced anti-C. muridarum protective immunity induced by Ag-specific CD4+ T cells is dependent upon IFN-gamma signaling and that such cells produce sufficient IFN-gamma to mediate the protective effects. Additionally, MHC class II pathway was sufficient for induction of robust protective anti-C. muridarum immunity. Thus, targeting soluble candidate Ags via MHC class II to CD4+ T cells may be a viable vaccine strategy to induce optimal IFN-gamma production for effective protective immunity against human genital chlamydial infection.
Li
Weidang
W
Department of Biology, South Texas Center for Emerging Infectious Diseases, University of Texas, San Antonio, TX 78249, USA.
Murthy
Ashlesh K
AK
Guentzel
M Neal
MN
Seshu
J
J
Forsthuber
Thomas G
TG
Zhong
Guangming
G
Arulanandam
Bernard P
BP
D000281:Administration, Intranasal; D019264:Adoptive Transfer; D000818:Animals; D017951:Antigen Presentation / Q000235:genetics; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000637:transplantation*; D002690:Chlamydia Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D023502:Chlamydia muridarum / Q000276:immunology*; D010450:Endopeptidases / Q000008:administration & dosage / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000172:deficiency / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000276:immunology; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology; D014623:Vaginal Diseases / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D001613:beta 2-Microglobulin / Q000172:deficiency / Q000235:genetics
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; C408982:CPG-oligonucleotide; D018984:Epitopes, T-Lymphocyte; D009838:Oligodeoxyribonucleotides; D001613:beta 2-Microglobulin; D007371:Interferon-gamma; D010450:Endopeptidases; C425923:CPA factor